top of page

Search Results

Diese Website durchsuchen

548 Ergebnisse gefunden mit einer leeren Suche

  • FDA clears Masimo smartSET atrial fibrillation detection capability for Radius VSM patient monitoring system

    The FDA has cleared Masimo's smartSET-powered atrial fibrillation detection capability for the Radius VSM patient monitoring system, expanding its continuous monitoring functionality. The newly cleared capability uses advanced pulse oximetry signal analysis to help clinicians identify patterns associated with atrial fibrillation during patient monitoring. Masimo's announcement also references opioid-induced respiratory depression detection, but that functionality received FDA clearance in June 2026 and is separate from the newly reportable AFib clearance. Field Content Article Type Approvals Device Name Radius VSM Technology Name smartSET Company Masimo Regulatory Authority U.S. Food and Drug Administration Regulatory Decision 510(k) clearance Newly Cleared Capability Atrial fibrillation detection Device Category Continuous patient monitoring system Underlying Technology Advanced pulse oximetry signal analysis Clinical Application Detection of signal patterns associated with atrial fibrillation during patient monitoring Therapeutic Area Cardiovascular monitoring; medical technology Target Condition Atrial fibrillation Platform Masimo Radius VSM Clinical Function Support clinician recognition of patterns associated with atrial fibrillation Approval Announcement Date 17 October 2026 Geography United States Related Capability Opioid-induced respiratory depression detection Earlier Regulatory Milestone Opioid-induced respiratory depression detection received FDA clearance in June 2026 Clinical Evidence Specific clinical performance metrics were not provided in the supplied summary What Happened The FDA granted 510(k) clearance for Masimo's smartSET-powered atrial fibrillation detection capability on the Radius VSM patient monitoring platform. Why It Matters The clearance expands the clinical monitoring functions available through Masimo's technology and may help clinicians recognise potential atrial fibrillation during continuous monitoring. Supporting Context The newly cleared AFib functionality is distinct from the previously cleared opioid-induced respiratory depression detection feature. Potential Impact The expanded capability could support broader use of continuous monitoring technology in clinical settings where recognition of cardiac rhythm abnormalities is important. Regulatory Context Medical device clearance rather than pharmaceutical marketing authorisation Key Takeaway Masimo has secured a new FDA clearance for atrial fibrillation detection using smartSET technology on Radius VSM; its opioid-related monitoring clearance dates to June 2026. What to Watch Commercial availability, hospital adoption, integration into clinical monitoring workflows, clinical performance evidence and future regulatory developments. Primary Source Masimo Primary Source URL https://www.masimo.com/media/masimos-smartset-tm-fda-clearance-offers-breakthrough-innovation-in-pulse-oximetry-to-help-improve-critical-patient-outcomes Relevant Date 17 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Biocon and Genentech reach global Pebrilzo biosimilar patent settlement establishing launch dates

    Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta. The agreement resolves pending patent disputes and permits Biocon to launch Pebrilzo in the EU and UK from the first quarter of 2027, in the United States from the third quarter of 2028 and in other territories according to agreed timelines. The settlement provides greater commercial planning certainty for the proposed oncology biosimilar, although actual launches remain subject to applicable regulatory approvals and market access requirements. Field Content Article Type Deals Companies Biocon; Genentech Deal Type Global patent settlement and licence agreement Product Pebrilzo Molecule Pertuzumab Reference Product Perjeta Therapeutic Area Oncology; HER2-targeted breast cancer treatment Agreement Scope Resolution of patent disputes and establishment of licensed biosimilar launch dates EU and UK Launch Window From Q1 2027 US Launch Window From Q3 2028 Other Territories During 2026–2028 or earlier in certain circumstances Financial Terms Not disclosed in supplied summary Regulatory Status Commercial launch remains subject to applicable marketing approvals Geography Global; including European Union, United Kingdom and United States What Happened Biocon and Genentech agreed to a global patent settlement permitting specified future launch windows for Pebrilzo. Why It Matters The agreement reduces patent-related uncertainty and establishes a clearer commercial pathway for a proposed pertuzumab biosimilar. Strategic Rationale Biocon secures licensed market-entry dates while Genentech resolves outstanding intellectual property disputes. Key Takeaway The settlement establishes commercial launch rights but does not itself constitute regulatory approval of Pebrilzo. What to Watch Regulatory decisions, launch execution, reimbursement arrangements and competitive dynamics in pertuzumab biosimilars. Primary Source Biocon announcement Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Eton licenses Aquestive's Libervant seizure rescue film for exclusive US commercialisation

    Eton Pharmaceuticals has secured exclusive US commercialisation rights to Aquestive Therapeutics' Libervant diazepam buccal film for the investigational treatment of seizure clusters. The licensing and supply agreement gives Eton responsibility for US commercialisation while Aquestive remains the exclusive manufacturer and supplier of the diazepam buccal film formulation. Aquestive is eligible for mid-teens royalties on annual net sales, with a potential April 2027 commercial launch dependent on final FDA approval. Field Content Article Type Deals Companies Eton Pharmaceuticals; Aquestive Therapeutics Deal Type Exclusive US licensing and supply agreement Licensed Product Libervant Active Ingredient Diazepam Dosage Form Buccal film Therapeutic Area Neurology; seizure clusters Product Status Investigational for the intended US commercial launch; final FDA approval pending Licensing Rights Exclusive US commercialisation rights granted to Eton Manufacturing and Supply Aquestive remains the exclusive manufacturer and supplier Royalties Mid-teens percentage of annual net sales Upfront Payment Not disclosed in supplied summary Expected Commercial Launch April 2027 subject to final FDA approval Geography United States What Happened Eton and Aquestive signed an exclusive US licensing and supply agreement for Libervant diazepam buccal film. Why It Matters The agreement establishes a dedicated commercial partner for a potential seizure-cluster rescue treatment while preserving Aquestive's manufacturing role. Strategic Rationale Eton gains a potential specialty neurology product while Aquestive retains supply responsibilities and participates in future sales through royalties. Key Takeaway Eton holds exclusive US commercialisation rights to Libervant but the product's anticipated launch depends on final FDA approval. What to Watch FDA regulatory decision, launch preparations, product availability, reimbursement and subsequent sales performance. Primary Source Eton Pharmaceuticals and Aquestive Therapeutics announcement Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Alaunos acquires Velaris Therapeutics alongside $350 million financing for pulmonary hypertension pipeline

    Alaunos Therapeutics has acquired Velaris Therapeutics in a stock-for-stock transaction supported by a separate $350 million financing to advance pulmonary hypertension treatments. The acquisition brings Velaris' investigational pulmonary arterial hypertension and cardiopulmonary programmes into Alaunos, with a private placement led by Fairmount and other investors providing development capital. The financing is distinct from the acquisition consideration and is expected to support the combined company's pipeline, with a projected cash runway extending into 2029. Field Content Article Type Deals Companies Alaunos Therapeutics; Velaris Therapeutics Deal Type Acquisition and concurrent private placement Acquirer Alaunos Therapeutics Target Velaris Therapeutics Acquisition Consideration Stock-for-stock transaction; valuation not specified in supplied summary Concurrent Financing $350 million private placement Financing Participants Fairmount and other investors Transaction Status Acquisition completed and announced Acquisition Date 13 October 2026 Therapeutic Areas Pulmonary arterial hypertension and related cardiopulmonary conditions Development Stage Investigational therapeutic pipeline Pipeline Origin Velaris Therapeutics; associated with Paragon Projected Cash Runway Into 2029 Geography United States What Happened Alaunos acquired Velaris Therapeutics through a stock-for-stock transaction accompanied by a separate $350 million private placement. Why It Matters The transaction repositions Alaunos around pulmonary hypertension development and provides substantial financing to support its investigational pipeline. Strategic Rationale The acquisition adds Velaris' cardiopulmonary programmes while the financing supports continued research and clinical development. Key Takeaway Alaunos has acquired Velaris and secured $350 million in financing; the financing amount should not be presented as the acquisition purchase price. What to Watch Lead programme development, clinical trial timelines, financing deployment and updated corporate pipeline guidance. Primary Source Alaunos Therapeutics investor announcement Relevant Date 13 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves expanded use of Gore VIABAHN VBX stent graft for complex aortic aneurysm repair

    The FDA has approved expanded use of Gore's VIABAHN VBX Balloon Expandable Endoprosthesis as a bridging stent graft for complex endovascular aortic aneurysm repair. The expanded indication permits use of the device in fenestrated and branched endovascular aortic repair, making it the first US on-label bridging stent option described for both FEVAR and BEVAR procedures. Three-year EMBRACE Registry data reported vessel-level primary patency rates of 97.5% for FEVAR and 94.0% for BEVAR, supporting the device's clinical role in complex aortic interventions. Field Content Article Type Approvals Device Name Gore VIABAHN VBX Balloon Expandable Endoprosthesis Company W. L. Gore & Associates Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Expanded-use approval Device Type Balloon-expandable covered stent graft New Clinical Application Bridging stent graft for fenestrated and branched endovascular aortic repair Procedures FEVAR; BEVAR Therapeutic Area Vascular surgery; complex aortic aneurysm repair Clinical Evidence EMBRACE Registry Three-Year Primary Patency in FEVAR 97.5% at the vessel level Three-Year Primary Patency in BEVAR 94.0% at the vessel level Approval Significance Described as the first US on-label bridging stent option for both FEVAR and BEVAR Geography United States What Happened The FDA approved expanded use of Gore's VIABAHN VBX endoprosthesis as a bridging stent graft in FEVAR and BEVAR procedures. Why It Matters The decision provides an on-label device option for complex aortic repairs involving fenestrated or branched endovascular techniques. Supporting Context The EMBRACE Registry reported high vessel-level primary patency at three years in both FEVAR and BEVAR procedures. Potential Impact The expanded indication may support broader clinical adoption and procedural standardisation in complex endovascular aortic repair. Key Takeaway Gore's VIABAHN VBX has received an expanded FDA indication supported by three-year registry outcomes. What to Watch Hospital adoption, longer-term vessel patency, device-related complications and future real-world clinical evidence. Primary Source W. L. Gore & Associates announcement Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Roche licenses Rona Therapeutics ALK7-targeting RNAi obesity therapy in deal worth up to $1.16 billion

    Roche has secured worldwide rights to Rona Therapeutics' investigational ALK7-targeting RNAi therapy in an obesity and metabolic disease licensing agreement worth up to $1.16 billion. The agreement covers an RNA interference candidate designed to target ALK7 using Rona's extrahepatic delivery technology, with the aim of developing a differentiated approach to metabolic disease treatment. Rona may receive up to $100 million in upfront and near-term payments, up to $1.06 billion in subsequent milestones and royalties, while the candidate's proposed effects on visceral fat and lean mass remain to be established clinically. Field Content Article Type Deals Companies Roche; Rona Therapeutics Deal Type Exclusive worldwide licensing agreement Potential Deal Value Up to $1.16 billion excluding royalties Upfront and Near-Term Payments Up to $100 million combined Subsequent Milestones Up to $1.06 billion Royalties Additional royalties; rates not disclosed in supplied summary Licensed Asset Investigational ALK7-targeting RNAi therapeutic candidate Molecular Target ALK7 Technology RNA interference with extrahepatic delivery Therapeutic Modality RNAi therapy Therapeutic Areas Obesity and metabolic diseases Development Stage Investigational; clinical development status not specified in supplied summary Licensing Rights Exclusive global rights obtained by Roche Geography Worldwide What Happened Roche entered a global licensing agreement for Rona Therapeutics' ALK7-targeting RNAi candidate. Why It Matters The collaboration broadens Roche's obesity and metabolic disease pipeline with a gene-silencing approach directed at adipose tissue biology. Strategic Rationale Roche gains access to an investigational metabolic target and Rona's delivery technology while Rona receives near-term funding and contingent milestone opportunities. Potential Impact The candidate could offer a differentiated obesity treatment strategy if its proposed metabolic benefits are confirmed in clinical studies. Key Takeaway Roche's agreement with Rona carries potential payments of up to $1.16 billion plus royalties; efficacy and safety remain investigational. What to Watch Clinical development plans, human efficacy and safety data, delivery performance and milestone payments. Primary Source Rona Therapeutics announcement Relevant Date 13 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Gilead signs Vir Biotechnology oncology collaboration worth up to $1.9 billion for masked T-cell engagers

    Gilead has entered a global oncology collaboration with Vir Biotechnology worth potentially $1.9 billion to develop masked T-cell engagers for solid tumours. The agreement gives Gilead exclusive licensing rights to three investigational T-cell engager candidates developed using Vir's PRO-XTEN dual-masking technology and AI-enabled protein engineering capabilities. Vir is eligible for $90 million in upfront consideration, including cash and equity, plus up to $45 million in near-term preclinical milestones and $1.74 billion in additional milestones, alongside royalties on future sales. Field Content Article Type Deals Companies Gilead Sciences; Vir Biotechnology Deal Type Global oncology licensing and collaboration agreement Potential Deal Value Approximately $1.9 billion including contingent payments Upfront Consideration $90 million comprising $65 million cash and $25 million equity investment Near-Term Milestones Up to $45 million in preclinical milestones Additional Milestones Up to $1.74 billion Royalties Royalties on future sales; rates not specified in supplied summary Licensed Assets Three investigational solid-tumour T-cell engager candidates Technology PRO-XTEN dual-masking technology and AI-enabled protein engineering Therapeutic Modality Masked T-cell engagers Therapeutic Area Oncology; solid tumours Development Stage Preclinical Licensing Rights Exclusive rights to three collaboration candidates Geography Global What Happened Gilead agreed to license three solid-tumour T-cell engager candidates from Vir Biotechnology in a global oncology collaboration. Why It Matters The agreement expands Gilead's access to next-generation immuno-oncology technology designed to improve the targeting of T-cell engager therapies. Strategic Rationale Gilead gains access to Vir's dual-masking platform while Vir receives financial support and potential downstream payments for its oncology assets. Key Takeaway The collaboration carries approximately $1.9 billion in potential consideration but most payments depend on future milestones. What to Watch Preclinical candidate progression, development milestones, clinical trial initiation and future programme disclosures. Primary Source Vir Biotechnology SEC filing Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Galderma agrees $1.5 billion acquisition of ZO Skin Health to expand dermatological skincare portfolio

    Galderma has agreed to acquire ZO Skin Health for an enterprise value of $1.5 billion, expanding its physician-dispensed dermatological skincare portfolio. The all-cash agreement covers 100% of ZO Skin Health and will add the company's professional skincare products to Galderma's dermatology business alongside its existing Alastin brand. The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions, and is intended to strengthen Galderma's position in medical aesthetics and skincare. Field Content Article Type Deals Companies Galderma; ZO Skin Health Deal Type Acquisition agreement Target Company ZO Skin Health Acquirer Galderma Enterprise Value $1.5 billion Transaction Structure All-cash acquisition of 100% of ZO Skin Health Sellers Shareholders including Blackstone-managed funds and the Obagi family Transaction Status Agreement signed; completion pending Expected Closing Fourth quarter of 2026 or early 2027 Closing Conditions Regulatory approvals and customary closing conditions Business Segment Physician-dispensed skincare and medical aesthetics Existing Portfolio Fit Complementary to Galderma's Alastin skincare business Geography International dermatology and skincare markets What Happened Galderma agreed to acquire ZO Skin Health in an all-cash transaction with an enterprise value of $1.5 billion. Why It Matters The acquisition would significantly expand Galderma's professional skincare portfolio and deepen its position in physician-dispensed dermatological products. Strategic Rationale Galderma aims to combine ZO Skin Health with its existing skincare capabilities to strengthen its presence in medical aesthetics and dermatology. Key Takeaway Galderma's proposed $1.5 billion acquisition of ZO Skin Health remains subject to closing conditions. What to Watch Regulatory approvals, transaction closing, brand integration and commercial performance following acquisition. Primary Source Galderma announcement Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Zealand Pharma signs AI protein therapeutics collaboration with Generate Biomedicines worth over $1 billion

    Zealand Pharma and Generate Biomedicines have signed an AI-enabled protein therapeutics collaboration for obesity and metabolic diseases with potential milestone payments approaching $1.2 billion. Generate will apply its generative AI platform to design multispecific protein therapeutics across two initial programmes, with an option to expand the collaboration to a third programme. Generate is set to receive $30 million upfront and may earn up to $35 million in early preclinical milestones, further contingent milestones and tiered royalties, while Zealand will lead subsequent clinical development and worldwide commercialisation. Field Content Article Type Deals Companies Zealand Pharma; Generate Biomedicines Deal Type Research collaboration and licensing agreement Upfront Payment $30 million Early Preclinical Milestones Up to $35 million Total Milestone Opportunity Approaching $1.2 billion across the initial programmes as described in the supplied summary Royalties Tiered royalties on future sales Initial Programmes Two Additional Programme Option Option for a third programme Technology Generative AI-enabled protein therapeutic design Therapeutic Modality Multispecific protein therapeutics Therapeutic Areas Obesity and other metabolic diseases Generate Responsibilities AI-enabled design and research-stage development of protein therapeutic candidates Zealand Responsibilities Subsequent clinical development and worldwide commercialisation Development Stage Research and discovery Geography Worldwide What Happened Zealand Pharma and Generate Biomedicines entered a collaboration to develop AI-engineered protein therapeutics for metabolic diseases. Why It Matters The partnership combines computational protein design with Zealand's metabolic disease development expertise to explore new therapeutic candidates. Strategic Rationale Generate contributes its generative AI platform while Zealand contributes clinical development and commercialisation capabilities in metabolic disease. Key Takeaway The agreement includes $30 million upfront and substantial contingent milestone opportunities; milestone categories should not be double-counted. What to Watch Programme target disclosures, candidate selection, exercise of the third-programme option and preclinical development milestones. Primary Source Generate Biomedicines announcement Relevant Date 13 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA expands Anktiva approval to high-grade papillary-only BCG-unresponsive bladder cancer

    The FDA has expanded Anktiva's approval to include adults with high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer, establishing the first approved treatment specifically for this population. Anktiva (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin is now authorised for eligible patients with high-grade papillary-only disease, extending its previous indication for carcinoma in situ-associated bladder cancer. The decision draws on evidence from the QUILT-3.032 development programme and regulatory consideration of related disease presentations, broadening treatment options for patients whose cancer has not responded to BCG. Field Content Article Type Approvals Drug Name Anktiva Generic Name Nogapendekin alfa inbakicept-pmln Company ImmunityBio Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Expanded indication approval New Indication BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumours Patient Population Adults with high-grade papillary-only BCG-unresponsive NMIBC Previously Approved Population BCG-unresponsive NMIBC with carcinoma in situ Treatment Regimen Anktiva in combination with bacillus Calmette-Guérin (BCG) Therapeutic Area Oncology; bladder cancer Therapeutic Modality IL-15 receptor agonist immunotherapy Clinical Evidence QUILT-3.032 development programme and supporting regulatory evidence Approval Significance First FDA-approved treatment specifically for the high-grade papillary-only BCG-unresponsive NMIBC population Geography United States What Happened The FDA expanded Anktiva's indication to include high-grade papillary-only BCG-unresponsive non-muscle invasive bladder cancer. Why It Matters The decision provides a newly authorised treatment option for a patient population with limited bladder-preserving therapeutic choices. Supporting Context The expanded indication builds on Anktiva's existing authorisation in BCG-unresponsive carcinoma in situ-associated disease. Key Takeaway Anktiva plus BCG is now FDA-approved for eligible adults with high-grade papillary-only BCG-unresponsive NMIBC. What to Watch Clinical guideline updates, physician adoption, reimbursement and longer-term treatment outcomes. Primary Source U.S. Food and Drug Administration Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Roche Tecentriq combination as first adjuvant immunotherapy for stage III dMMR colon cancer

    The FDA has approved Roche's Tecentriq-based chemotherapy regimen as the first adjuvant immunotherapy option for eligible patients with stage III mismatch repair-deficient colon cancer. The approval covers Tecentriq (atezolizumab) and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin chemotherapy for adjuvant treatment of stage III dMMR colon cancer. In the Phase III ATOMIC trial, the immunotherapy combination reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, establishing a new treatment option following surgery. Field Content Article Type Approvals Drug Names Tecentriq; Tecentriq Hybreza Generic Name Atezolizumab Company Roche Regulatory Authority U.S. Food and Drug Administration Approval Type New adjuvant treatment indication Indication Stage III mismatch repair-deficient colon cancer Patient Population Eligible patients with stage III dMMR colon cancer Therapy Area Oncology; colorectal cancer Technology/Modality PD-L1 checkpoint inhibitor immunotherapy Approved Regimen Atezolizumab or atezolizumab and hyaluronidase-tqjs in combination with fluoropyrimidine and oxaliplatin chemotherapy Treatment Setting Adjuvant treatment following surgery Clinical Study Phase III ATOMIC Key Clinical Finding 50% reduction in the risk of disease recurrence or death compared with chemotherapy alone Biomarker Mismatch repair deficiency (dMMR) Geography United States What Happened The FDA approved Tecentriq and Tecentriq Hybreza in combination with fluoropyrimidine and oxaliplatin chemotherapy for adjuvant treatment of eligible patients with stage III dMMR colon cancer. Why It Matters The decision establishes the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer and introduces a biomarker-directed treatment option in this setting. Supporting Context The Phase III ATOMIC study demonstrated a 50% reduction in the risk of recurrence or death with the atezolizumab-containing regimen compared with chemotherapy alone. Potential Impact The approval could change postoperative treatment pathways for eligible patients with stage III dMMR colon cancer. Key Takeaway Roche has secured FDA approval for a Tecentriq-based adjuvant regimen in stage III dMMR colon cancer following positive Phase III ATOMIC results. What to Watch Updated oncology guidelines, biomarker testing practices, clinical adoption, reimbursement and longer-term survival outcomes. Primary Source Roche Relevant Date 8 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA clears Endovascular Engineering Hēlo thrombectomy and blood-return systems for pulmonary embolism treatment

    The FDA has granted 510(k) clearances for Endovascular Engineering's Hēlo thrombectomy and blood-return systems, advancing an integrated approach to pulmonary embolism treatment. The Hēlo Thrombectomy System uses continuous vacuum aspiration to remove thrombotic material, while the Hēlo Return system is designed to support blood recovery during interventional procedures. The clearances establish an important regulatory milestone for the combined platform, which aims to support effective clot removal while limiting procedural blood loss in pulmonary embolism interventions. Field Content Article Type Approvals Device Names Hēlo Thrombectomy System; Hēlo Return Company Endovascular Engineering Regulatory Authority U.S. Food and Drug Administration Regulatory Decision 510(k) clearances Approval Type Medical device clearance Clinical Application Pulmonary embolism thrombectomy Therapy Area Interventional cardiovascular medicine; pulmonary embolism Technology/Modality Mechanical thrombectomy using continuous vacuum aspiration with an integrated blood-return system Thrombectomy Component Hēlo Thrombectomy System Blood Management Component Hēlo Return System Function Aspiration-based thrombus removal with blood recovery capabilities Intended Clinical Benefit Support clot removal while limiting procedural blood loss Geography United States What Happened The FDA granted 510(k) clearances for Endovascular Engineering's Hēlo Thrombectomy System and Hēlo Return blood-return system. Why It Matters The clearances advance an integrated thrombectomy platform designed to address both clot removal and blood management during pulmonary embolism procedures. Supporting Context Continuous vacuum aspiration can facilitate mechanical clot extraction, while the blood-return component is intended to reduce procedural blood loss. Potential Impact The platform could expand device options for clinicians performing catheter-based pulmonary embolism interventions. Key Takeaway Endovascular Engineering has received FDA 510(k) clearances for its Hēlo thrombectomy and blood-return systems. What to Watch US commercial availability, hospital adoption, clinical performance data, procedural outcomes and integration into pulmonary embolism treatment pathways. Primary Source Diagnostic and Interventional Cardiology Relevant Date 12 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page